115 related articles for article (PubMed ID: 37265367)
1. Differences in adjuvant chemotherapy and oncological outcomes according to margin status in patients with stage III colon cancer.
Smith HG; Skovgaards DM; Bui NH; Chiranth D; Qvortrup C; Schlesinger NH
Acta Oncol; 2023 Jun; 62(6):594-600. PubMed ID: 37265367
[TBL] [Abstract][Full Text] [Related]
2. Do differences in surgical quality account for the higher rate of R1 margins to lymph node metastases in right- versus left-sided Stage III colon cancer: A retrospective cohort study.
Smith HG; Chiranth DJ; Schlesinger NH
Colorectal Dis; 2023 Apr; 25(4):679-687. PubMed ID: 36565048
[TBL] [Abstract][Full Text] [Related]
3. The impact of subdivisions of microscopically positive (R1) margins on patterns of relapse in stage III colorectal cancer - A retrospective cohort study.
Smith HG; Skovgaards DM; Chiranth D; Schlesinger NH
Colorectal Dis; 2022 Jul; 24(7):828-837. PubMed ID: 35304974
[TBL] [Abstract][Full Text] [Related]
4. The significance of subdivisions of microscopically positive (R1) margins in colorectal cancer: A retrospective study of a national cancer registry.
Smith HG; Chiranth D; Mortensen CE; Schlesinger NH
Colorectal Dis; 2022 Feb; 24(2):197-209. PubMed ID: 34714581
[TBL] [Abstract][Full Text] [Related]
5. Impact of Anatomic Extent of Nodal Metastasis on Adjuvant Chemotherapy Outcomes in Stage III Colon Cancer.
Woo IT; Park JS; Kang BW; Park SY; Kim HJ; Choi GS; Gwang Kim J
Dis Colon Rectum; 2020 Oct; 63(10):1455-1465. PubMed ID: 32969889
[TBL] [Abstract][Full Text] [Related]
6. Prognostic and predictive roles of DNA mismatch repair status in colon cancer patients treated with oxaliplatin-based chemotherapy: a retrospective study.
Qin Q; Zhou AP; Yang L; Xu C; Sun YK; Zhang W; Wang JW; Zhong DS
J Physiol Pharmacol; 2020 Aug; 71(4):. PubMed ID: 33316771
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant Chemotherapy for Locally Advanced T4 Colon Cancer: A Nationwide Propensity-Score Matched Cohort Analysis.
de Gooyer JM; Verstegen MG; 't Lam-Boer J; Radema SA; Verhoeven RHA; Verhoef C; Schreinemakers JMJ; de Wilt JHW
Dig Surg; 2020; 37(4):292-301. PubMed ID: 31661689
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial.
de Gramont A; Van Cutsem E; Schmoll HJ; Tabernero J; Clarke S; Moore MJ; Cunningham D; Cartwright TH; Hecht JR; Rivera F; Im SA; Bodoky G; Salazar R; Maindrault-Goebel F; Shacham-Shmueli E; Bajetta E; Makrutzki M; Shang A; André T; Hoff PM
Lancet Oncol; 2012 Dec; 13(12):1225-33. PubMed ID: 23168362
[TBL] [Abstract][Full Text] [Related]
9. Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy.
Kim ST; Lee J; Park SH; Park JO; Lim HY; Kang WK; Kim JY; Kim YH; Chang DK; Rhee PL; Kim DS; Yun H; Cho YB; Kim HC; Yun SH; Lee WY; Chun HK; Park YS
Cancer Chemother Pharmacol; 2010 Sep; 66(4):659-67. PubMed ID: 20033812
[TBL] [Abstract][Full Text] [Related]
10. The impact of adjuvant oxaliplatin and tumor sidedness on the overall survival of stage IIB colon cancer patients: a multicentre study.
Atci MM; Akagunduz B; Demir M; Arikan R; Ay S; Ozer M; Ayhan M; Cil I; Demir N; Ozyurt N; Karakaya G; Cevik GT; Onder AH; Selvi O; Sakin A
J Chemother; 2023 Feb; 35(1):19-28. PubMed ID: 35174772
[TBL] [Abstract][Full Text] [Related]
11. Effect of Margin Status on Survival After Resection of Hilar Cholangiocarcinoma in the Modern Era of Adjuvant Therapies.
Watson MD; Baimas-George MR; Passeri MJ; Sulzer JK; Baker EH; Ocuin LM; Martinie JB; Iannitti DA; Vrochides D
Am Surg; 2021 Sep; 87(9):1496-1503. PubMed ID: 33345594
[TBL] [Abstract][Full Text] [Related]
12. Benefit of Oxaliplatin in Stage III Colon Cancer According to IDEA Risk Groups: Findings from the ACCENT Database of 4934 Patients.
Margalit O; Boursi B; Rakez M; Thierry A; Yothers G; Wolmark N; Haller DG; Schmoll HJ; Shi Q; Shacham-Shmueli E; de Gramont A
Clin Colorectal Cancer; 2021 Jun; 20(2):130-136. PubMed ID: 33775561
[TBL] [Abstract][Full Text] [Related]
13. Stage III Colon Cancer: The Individualized Strategy of Adjuvant Chemotherapy for Aged Under and Over 70.
Lu CS; Chang PY; Chen YG; Chen JH; Wu YY; Ho CL
PLoS One; 2015; 10(9):e0138632. PubMed ID: 26382962
[TBL] [Abstract][Full Text] [Related]
14. Impact of Metformin Use and Diabetic Status During Adjuvant Fluoropyrimidine-Oxaliplatin Chemotherapy on the Outcome of Patients with Resected Colon Cancer: A TOSCA Study Subanalysis.
Vernieri C; Galli F; Ferrari L; Marchetti P; Lonardi S; Maiello E; Iaffaioli RV; Zampino MG; Zaniboni A; De Placido S; Banzi M; Damiani A; Ferrari D; Rosati G; Labianca RF; Bidoli P; Frassineti GL; Nicolini M; Pavesi L; Tronconi MC; Buonadonna A; Ferrario S; Re GL; Adamo V; Tamburini E; Clerico M; Giordani P; Leonardi F; Barni S; Ciarlo A; Cavanna L; Gori S; Cinieri S; Faedi M; Aglietta M; Antista M; Dotti KF; Galli F; Di Bartolomeo M;
Oncologist; 2019 Mar; 24(3):385-393. PubMed ID: 30606884
[TBL] [Abstract][Full Text] [Related]
15. Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Taieb J; Tabernero J; Mini E; Subtil F; Folprecht G; Van Laethem JL; Thaler J; Bridgewater J; Petersen LN; Blons H; Collette L; Van Cutsem E; Rougier P; Salazar R; Bedenne L; Emile JF; Laurent-Puig P; Lepage C;
Lancet Oncol; 2014 Jul; 15(8):862-73. PubMed ID: 24928083
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC): a multicentre, open-label, randomised trial.
Klaver CEL; Wisselink DD; Punt CJA; Snaebjornsson P; Crezee J; Aalbers AGJ; Brandt A; Bremers AJA; Burger JWA; Fabry HFJ; Ferenschild F; Festen S; van Grevenstein WMU; Hemmer PHJ; de Hingh IHJT; Kok NFM; Musters GD; Schoonderwoerd L; Tuynman JB; van de Ven AWH; van Westreenen HL; Wiezer MJ; Zimmerman DDE; van Zweeden AA; Dijkgraaf MGW; Tanis PJ;
Lancet Gastroenterol Hepatol; 2019 Oct; 4(10):761-770. PubMed ID: 31371228
[TBL] [Abstract][Full Text] [Related]
17. Clinical impact of elastic laminal invasion in colon cancer: elastic laminal invasion-positive stage II colon cancer is a high-risk equivalent to stage III.
Yokota M; Kojima M; Nomura S; Nishizawa Y; Kobayashi A; Ito M; Ochiai A; Saito N
Dis Colon Rectum; 2014 Jul; 57(7):830-8. PubMed ID: 24901683
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant chemotherapy in locally advanced colon cancer: a systematic review and meta-analysis.
Gosavi R; Chia C; Michael M; Heriot AG; Warrier SK; Kong JC
Int J Colorectal Dis; 2021 Oct; 36(10):2063-2070. PubMed ID: 33945007
[TBL] [Abstract][Full Text] [Related]
19. Utilization and impact of adjuvant chemotherapy among patients with resected stage II colon cancer: a multi-institutional analysis.
Ejaz A; Casadaban L; Maker AV
J Surg Res; 2017 Jul; 215():12-20. PubMed ID: 28688636
[TBL] [Abstract][Full Text] [Related]
20. Practical outcome of adjuvant FOLFOX4 chemotherapy in elderly patients with stage III colon cancer: single-center study in Korea.
Kim JY; Kim YJ; Lee KW; Lee JS; Kim DW; Kang SB; Lee HS; Jang NY; Kim JS; Kim JH
Jpn J Clin Oncol; 2013 Feb; 43(2):132-8. PubMed ID: 23204187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
